- > Frequently Asked Questions (FAQ) on Mouse Models for Ophthalmic Diseases
- > Revolutionizing Neovascular Ophthalmology Research: Cyagen's Phenotypically Stable Humanized VEGF Mice
- > Vision Stolen by Years - Age-related Macular Degeneration
- > Accelerating CAR-T Cell Therapy Research
- > Preclinical Pharmacological Model of CAR T-Cell Therapy
Most Popular
|
Breaking News
Newsletter
|
| Cyagen and Biointron Announce Strategic Alliance to Advance Antibody Drug Discovery |
| Mar 28, 2024 |
| Cyagen Biosciences (Suzhou) Inc. (“Cyagen Biosciences”) and Shanghai BaiYing Bio-Technology Co., Ltd. (“Biointron”) have signed a strategic cooperation agreement. Read More > |
|
Research Trends
|
| Hemophilia B Disease Model - F9 Knockout Mice |
| Mar 21, 2024 |
| In this issue, we introduce the Hemophilia B disease mouse model - F9 Knockout (KO) Mice. Hemophilia is a group of hereditary bleeding disorders characterized by a deficiency in clotting factor activity, leading to prolonged clotting time and a risk of bleeding even after minor injuries. Read More > |
|
Research Trends
|
| Searching for Better Lung Cancer Models - KS Mice |
| Mar 18, 2024 |
| In this issue, we introduce the KS mouse model of lung cancer, based on the most common cancer-associated K-Ras mutant, K-Ras(G12D). Lung cancer is the most common cancer worldwide, with over 2.2 million new cases reported globally in 2020. According to data released by the Chinese National Cancer Center, lung cancer had already become the leading cause of morbidity and mortality among all malignant tumors in China by 2015. Read More > |
|
Research Trends
|
| Beta Thalassemia Research: Hbb-bs&Hbb-bt DKO Mouse Models |
| Mar 14, 2024 |
| In this edition, we provide an overview of Beta Thalassemia (β-thalassemia), a genetic blood disorder caused by reduced or absent synthesis of the beta globin (β-globin) chain of hemoglobin, and introduce Hbb-bs&Hbb-bt DKO mice as a promising Beta-thalassemia research model for preclinical therapeutics. Beta-thalassemia is one of the global social and public health issues monitored by the World Health Organization (WHO). Read More > |
|
Research Trends
|
| Small Nucleic Acid Drug Evaluation Model for Spinal Muscular Atrophy Research - B6-hSMN2(SMA) Mice |
| Feb 29, 2024 |
| Today, we'll be introducing a model of Spinal Muscular Atrophy (SMA) - B6-hSMN2(SMA) mice. But before delving into this mouse model, let's first introduce the basic pathology of SMA. Read More > |
|
Research Trends
|
| Preclinical R&D Interest Soars as the First AAV Gene Therapy for DMD Hits $200 Million in Sales |
| Feb 22, 2024 |
| Jointly developed by Sarepta Therapeutics and Roche, ELEVIDYS is an adeno-associated virus vector-based gene therapy indicated for the treatment of ambulatory pediatric patients aged 4 - 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. The United States Food and Drug Administration authorized accelerated approval for this indication based on expression of ELEVIDYS micro-dystrophin in skeletal muscle observed in patients treated with ELEVIDYS in June 2023. Read More > |
|
Research Trends
|
| Obesity Research Mice Introduction (Part 2): Non-LEP/LEPR Genetic Models |
| Feb 18, 2024 |
| In our previous article, we provided an “Introduction to Murine Models of Obesity (Part 1): LEP/LEPR Classic Pathway Model”. In this edition, we will delve into non-LEP/LEPR genetic mouse models for obesity research. Read More > |
|
Research Trends
|
| Introduction to Murine Models of Obesity (Part 1): LEP/LEPR Classic Pathway Model |
| Jan 31, 2024 |
| To effectively conduct research on obesity and its prevention and treatment, it is crucial to comprehend the mechanisms underlying obesity. Leveraging mouse models of obesity-related diseases is essential for gaining meaningful insights into the prevention and treatment of obesity and its complications. Read More > |
|
Research Trends
|
| Challenges of Performing Orthotopic Colorectal Cancer Modeling: Evaluating the Effectiveness of Modeling Site Exploration |
| Jan 26, 2024 |
| Colorectal cancer is a common malignant tumor that occurs in the colon, predominantly in the junction between the rectum and sigmoid colon. It ranks as the third most common gastrointestinal tumor with the highest incidence in the age group of 40 to 50 years, with a male-to-female ratio of 2-3:1. Read More > |
|
Newsletter
Breaking News
|
| Cyagen Congratulates Our Partner INNOVEC on Receiving FDA Pediatric Rare Disease Designation (RPDD) for IVB102 Injection |
| Jan 23, 2024 |
| The United States Food and Drug Administration (FDA) granted Beijing InnoVec Biotherapeutics’ InnoVex IVB102 injection the Rare Pediatric Disease Designation (RPDD) on January 10, 2024. Innovec is now one step closer to being eligible for the Rare Pediatric Disease Priority Review Voucher (PRV) for the treatment of rare pediatric diseases with the InnoVex IVB102 injection in the United States. Read More > |
